Rigel Pharmaceuticals, Inc. - Common Stock (RIGL)

The three major indices were mostly flat in midday trading Wednesday with the S&P 500 and Nasdaq slightly under the flatline and the Dow Jones up 39 points. 

U.S. stocks plunged Tuesday as President Donald Trump‘s tariffs on key trade partners came into effect, prompting retaliatory measures and intensifying global trade tensions.

The intense retail focus on Anavex reflects a broader market interest in neurodegenerative therapies, especially following disappointing trial results from Cassava Sciences’ simufilam.

RIGL stock results show that Rigel Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

You don’t want to overlook these three penny stocks filled to the brim with the potential to make huge leaps in their respective markets.

RIGL stock results show that Rigel Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

RIGL stock results show that Rigel Pharmaceuticals beat on revenue for the fourth quarter of 2023.

Although you can try your hand at the lottery, your odds of success are probably far better with stocks with high returns.

Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2.29 billion.

Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter.

Explore the world of high-risk, high-reward top penny stocks to buy and uncover promising investment opportunities.